Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 9—September 2022
Research Letter

Invasive Meningococcal X Disease during the COVID-19 Pandemic, Brazil

Lucila O. Fukasawa, Bernadete L. Liphaus, Maria Gisele Gonçalves, Fabio T. Higa, Carlos H. Camargo, Telma R.M.P. Carvalhanas, and Ana Paula S. LemosComments to Author 
Author affiliations: Adolfo Lutz Institute, São Paulo, Brazil (L.O. Fukasawa, M.G. Gonçalves, F.T. Higa, C.H. Camargo, A.P.S. Lemos); Epidemiological Surveillance Center “Professor Alexandre Vranjac,” São Paulo (B.L. Liphaus, T.R.M.P. Carvalhanas)

Cite This Article


Invasive meningococcal disease persists as a fulminant disorder worldwide. Although cases caused by Neisseria meningitidis serogroup X (MenX) occur infrequently, outbreaks have been reported in countries in Africa in recent decades. We report 2 cases of MenX invasive meningococcal disease in São Paulo, Brazil, in 2021 and 2022, during the COVID-19 pandemic.

Invasive meningococcal disease (IMD) is a severe disorder that is associated with high rates of morbidity and mortality worldwide (1). Although 12 serogroups of Neisseria meningitidis have been characterized based on their capsular polysaccharides, most IMD cases are caused by serogroups A, B, C, W, Y, and, more rarely, X (1).

N. meningitidis serogroup X (MenX) has been responsible for limited IMD cases in the United States and Europe, but since 1990, MenX isolates have emerged in some countries within the meningitis belt of Africa, causing outbreaks and epidemics in Burkina Faso, Togo, Niger, Kenya, and Uganda (2). In Brazil, only 6 cases of MenX IMD cases were reported in the last 15 years; the last one was isolated in the city of São Paulo in 2017 ( We report 2 cases of MenX IMD that occurred in São Paulo in 2021 and 2022, during the COVID-19 pandemic. These isolates were identified during routine laboratory-based public health surveillance in the National Reference Laboratory at the Adolfo Lutz Institute in São Paulo.

Case-patient 1 was a 7-month-old boy who, in November 2021, was admitted to a São Paulo emergency department with fever, vomiting, bulging anterior fontanelle, stiff neck, and seizure. Cerebrospinal fluid collected at that time revealed a leukocyte count of 1,440 cells/mm3 with a 73% proportion of neutrophils; protein level was 263 mg/dL, glucose 19 mg/dL, and lactate 80.5 mg/dL, and results of bacterioscopy and culture were negative. The patient was treated with ceftriaxone (100 mg/kg every 12 h) for 10 days, with a favorable outcome.

Case-patient 2 was a 6-year old boy who, in January 2022, was admitted to a São Paulo City emergency department with fever, headache, and vomiting. A sample of cerebrospinal fluid revealed a leukocyte count of 4920/mm3 with a 96% proportion of neutrophils; protein level was 207 mg/dL, glucose 48 mg/dL, and lactate 82.3 mg/dL, and results for bacterioscopy and culture were negative. The patient was treated with ceftriaxone (100 mg/kg every 12 h), the recommended antibiotic, with a favorable outcome.

Because both patients were diagnosed with meningitis, chemoprophylaxis with rifampin was administered to all persons characterized as close contacts. Both patients resided in the city of São Paulo but in different regions, 40 km away from each other. Despite the short period between their illnesses, epidemiologic surveillance could not establish an obvious relationship between the 2 patients. Neither patient had traveled to countries with reported MenX disease, nor had they had known contact with other persons diagnosed with meningitis.

We extracted DNA from the cerebrospinal fluid samples obtained from the 2 patients using the Roche MagNa Pure LC 2.0 platform ( according to the manufacturer’s instructions. Both DNA samples were positive for N. meningitidis (ctrA gene) by multiplex real-time PCR (3), and these results were confirmed using another real-time PCR targeting the meningococcal sodC gene (4). Both samples were positive for genogroup X (xcbB gene) by multiplex real-time PCR and negative for genogroups A, B, C, W, and Y (5).

A previous study demonstrated that the 413 bp fragment of the rplF gene, which encodes the 50S ribosomal protein L6, is a suitable genetic target for differentiating species within the genus Neisseria (6). A sequence analysis of the rplF gene of both of our patient samples revealed an rplF fragment assigned to allele 1, confirming the genospecies N. meningitidis (6). We conducted multilocus sequence typing according to standard protocols using the the PubMLST database ( and identified Nm400, the isolate from case-patient 2, as sequence type 2888, which is not assigned to a clonal complex. Because of the unavailability of clinical material for Nm111, the isolate from case-patient 1, multilocus sequence typing could not be performed for that isolate.

According to the PubMLST database (as of March 12, 2022), there are 4 records of ST2888: 1 is serogroup X, 2 are serogroup B, and 1 isolate did not have a serogroup recorded. Only 1 case of IMD caused by MenX ST2888 was reported, in Italy in 2009, in a patient who had not traveled abroad and who had a favorable outcome (7).

A large study in sub-Saharan Africa showed that the current population structure reveals MenX to be of a predominantly single lineage—ST181 of MenX belongs to a single main lineage, ST181 (clonal complex 181)—which is unlike the diversified MenX population found in Europe (8). A recent study in Italy described 4 cases of serogroup X IMD among refugees: 3 were immigrants from Africa, and the other was an immigrant from Bangladesh who had been in contact with refugees from Africa for several months. This highlights the potential threat of new lineages being introduced into vulnerable populations in times of humanitarian crises and conflicts (9).

Given the COVID-19 pandemic scenario that has brought an interruption in nonpharmacologic measures to control SARS-CoV-2 transmission, and considering the globally observed reduction of meningococcal vaccination coverage (10), a resurgence in cases of IMD will be likely, and cases of non–vaccine-preventable serogroup X should be monitored. Ongoing surveillance of IMD, as well as addition of surveillance initiatives in some regions, will be needed to ensure a successful public health response in terms of both prevention and control.

Dr. Fukasawa is a pharmacist and scientific researcher whose primary research interests include molecular surveillance of bacterial diseases caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae.



The authors thank the laboratory technicians of Santo André Adolfo Lutz Institute and Hospitals as well as the local epidemiologic surveillance staff.

Our team made use of the Neisseria Multi Locus Sequence Typing website ( neisseria/), developed by Keith Jolley and sited at the University of Oxford. The development of this site has been funded by the Wellcome Trust and European Union.



  1. Chang  Q, Tzeng  YL, Stephens  DS. Meningococcal disease: changes in epidemiology and prevention. Clin Epidemiol. 2012;4:23745.PubMedGoogle Scholar
  2. Mustapha  MM, Harrison  LH. Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. Hum Vaccin Immunother. 2018;14:110715. DOIPubMedGoogle Scholar
  3. Sacchi  CT, Fukasawa  LO, Gonçalves  MG, Salgado  MM, Shutt  KA, Carvalhanas  TR, et al.; São Paulo RT-PCR Surveillance Project Team. Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil. PLoS One. 2011;6:e20675. DOIPubMedGoogle Scholar
  4. Dolan Thomas  J, Hatcher  CP, Satterfield  DA, Theodore  MJ, Bach  MC, Linscott  KB, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS One. 2011;6:e19361. DOIPubMedGoogle Scholar
  5. Wang  X, Theodore  MJ, Mair  R, Trujillo-Lopez  E, du Plessis  M, Wolter  N, et al. Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens. J Clin Microbiol. 2012;50:7028. DOIPubMedGoogle Scholar
  6. Bennett  JS, Watkins  ER, Jolley  KA, Harrison  OB, Maiden  MCJ. Identifying Neisseria species by use of the 50S ribosomal protein L6 (rplF) gene. J Clin Microbiol. 2014;52:137581. DOIPubMedGoogle Scholar
  7. Fazio  C, Starnino  S, Solda  MD, Sofia  T, Neri  A, Mastrantonio  P, et al. Neisseria meningitidis serogroup X sequence type 2888, Italy. Emerg Infect Dis. 2010;16:35960. DOIPubMedGoogle Scholar
  8. Agnememel  A, Hong  E, Giorgini  D, Nuñez-Samudio  V, Deghmane  AE, Taha  MK. Neisseria meningitidis serogroup X in sub-Saharan Africa. Emerg Infect Dis. 2016;22:698702. DOIPubMedGoogle Scholar
  9. Stefanelli  P, Neri  A, Vacca  P, Picicco  D, Daprai  L, Mainardi  G, et al. Meningococci of serogroup X clonal complex 181 in refugee camps, Italy. Emerg Infect Dis. 2017;23:8702. DOIPubMedGoogle Scholar
  10. Alderson  MR, Arkwright  PD, Bai  X, Black  S, Borrow  R, Caugant  DA, et al. Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review. J Infect. 2022;84:28996. DOIPubMedGoogle Scholar


Cite This Article

DOI: 10.3201/eid2809.220531

Original Publication Date: August 11, 2022

Table of Contents – Volume 28, Number 9—September 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Ana Paula S. Lemos, Centro de Bacteriologia, Instituto Adolfo Lutz, Avenida Dr Arnaldo, 355, Pacaembu, São Paulo CEP 01246-902, Brazil

Send To

10000 character(s) remaining.


Page created: August 04, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.